In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy
Authors Shao Y, Luo W, Guo Q, Li X, Zhang Q, Li J
Received 24 January 2019
Accepted for publication 16 April 2019
Published 28 June 2019 Volume 2019:13 Pages 2043—2055
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Dr Qiongyu Guo
Yanping Shao,1 Wenda Luo,1 Qunyi Guo,1 Xiaohong Li,2 Qianqian Zhang,2 Jing Li2
1Department of Hematology-Oncology, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang 317000, People’s Republic of China; 2Department of Hematology, Hebei Province Hospital of Chinese Medicine, Shijiazhuang, Hebei 050011, People’s Republic of China
Objective: To investigate the hyaluronic acid (HA) modified, doxorubicin (DOX) and gallic acid (GA) co-delivered lipid-polymeric hybrid nano-system for leukemia therapy.
Methods: We produced a kind of lipid-polymer hybrid nanoparticle (LPHN) with a core-shell structure in which DOX and GA were co-loaded. In vitro and in vivo leukemia therapeutic effects of the HA modified, DOX and GA co-delivered LPHNs (HA-DOX/GA-LPHNs) were evaluated in DOX resistant human HL-60 promyelocytic leukemia cells (HL-60/ADR cells), DOX resistant human K562 chronic myeloid leukemia cells (K562/ADR cells), and HL-60/ADR cells bearing mouse model.
Results: The sizes and zeta potentials of HA modified LPHNs were about 160 nm and −40 mV. HA-DOX/GA-LPHNs showed the most prominent cytotoxicity and the best synergistic effect was obtained when DOX/GA ratio was 2/1. In vivo studies revealed that HA-DOX/GA-LPHNs inhibited tumor growth from 956 mm3, to 213 mm,3 with an inhibition rate of 77.7%.
Conclusion: In summary, the study showed that HA-DOX/GA-LPHNs can be applied as a promising leukemia therapy system.
Keywords: acute myeloid leukemia, doxorubicin, gallic acid, multidrug resistance, lipid-polymer hybrid nanoparticles
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]